Search

Displaying results 2221 - 2230 of 2955 in total
  1. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor

  2. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.

  3. Drug

    Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11002
    ApprovedWithdrawn

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...

    Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019, Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016
  4. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

    Synonyms: Rubivirus rubella virus Wistar RA 27/3 whole, Rubella virus strain Wistar RA 27/3 live antigen
  5. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.

  6. Drug

    Magnesium cation

    go.drugbank.com/drugs/DB01378
    ApprovedInvestigationalNutraceuticalWithdrawn

    Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used...

    Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADET
  7. Drug

    Beroctocog alfa

    go.drugbank.com/drugs/DB14473
    ApprovedInvestigational

    Mixtures: ALPHANATE FOR INJECTION 250 iu/vial, ALPHANATE FOR INJECTION 1000 iu/vialProducts: FEIBA 1000 U IV INFUZYON ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET, KOATE-DVI 250 IU/5 ML IV ENJEKSİYON İÇİN LİYOFİLZE TOZ İÇEREN FLAKON
  8. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB

  9. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis. … [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with

  10. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071] … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic